Freedom Capital Markets Downgrades Amgen (AMGN) to Hold (mid morning)

Freedom Capital Markets downgraded Amgen (NASDAQ: AMGN) from Buy to Hold.

The analyst comments "Amgen delivered a strong Q4 print, with results materially ahead of our expectations. Core growth drivers remain intact, and newer products continue to deliver impressive momentum. The low-end of revenue guidance for 2026 exceeded our forecasts, although the company cautioned that top-line pressure will persist from biosimilar launches for Prolia and XGEVA. Incorporating the updated outlook, we have raised our revenue and EPS estimates. We lift our price target to $375 from $360, but downgrade the rating from Buy to Hold, as shares are now approaching fair value and key loss-of-exclusivity (LOE) headwinds remain."

For an analyst ratings summary and ratings history on Amgen click here. For more ratings news on Amgen click here.

Shares of Amgen closed at $366.58 yesterday.

You May Also Be Interested In

• BofA Securities Starts Kanzhun Ltd. (BZ) at Neutral
• Yalla Group Limited (YALA) Reports Q2 EPS of $0.24
• XP Inc. (XP) Tops Q2 EPS by 8c